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1  | INTRODUC TION
Cholestatic liver diseases arise from any situation associated with 
impaired bile flow, as a result of disturbed hepatobiliary production 
or bile excretion, accompanied by noxious bile acid accumulation in 
hepatocytes or systemic circulation.1 The word cholestasis is derived 
from Greek (ie ‘chole’ and ‘stasis’) and literally means ‘bile halting’.2 A 
schematic overview of the pathogenesis of cholestasis is provided in 
Figure 1. Different types of cholestasis can be divided depending on 
specific underlying mechanisms and aetiology, such as biliary atresia, 
 
Received: 7 August 2020  |  Revised: 8 January 2021  |  Accepted: 15 January 2021
DOI: 10.1111/liv.14800  
R E V I E W  A R T I C L E
Rodent models of cholestatic liver disease: A practical guide for 
translational research
Eva Gijbels1,2 |   Alanah Pieters1 |   Kevin De Muynck2,3 |   Mathieu Vinken1 |   
Lindsey Devisscher2
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial- NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non- commercial and no modifications or adaptations are made.
© 2021 The Authors. Liver International published by John Wiley & Sons Ltd.
Mathieu Vinken and Lindsey Devisscher share equal seniorship. 
Abbreviations: AE2, anion exchange protein 2; AMA, antimitochondrial antibody; ANIT, α- naphtylisothiocyanate; ARE(- Del), (deletion in) adenylate- uridylate- rich element; ATP8B1, 
ATPase phospholipid transporting 8B1; BDL, bile duct ligation; BRIC, benign recurrent intrahepatic cholestasis; BSEP, bile salt export pump; CD, cluster of differentiation; CFTR, cystic 
fibrosis transmembrane conductance regulator; DDC, 3,5- diethoxycarbonyl- 1,4- dihydrocollidine; DIC, drug- induced cholestasis; DSS, dextran sodium sulphate; (dn)TGF- β(RII) mice, 
(dominant negative form of) transforming growth factor- β (receptor restricted to T cells); Foxp3, Forkhead box protein 3; IBD, inflammatory bowel diseases; ICP, intrahepatic cholestasis 
of pregnancy; idd, insulin- dependent diabetes; IL- 2(Rα), interleukin 2 (receptor α); MDR, multidrug resistance protein; MRP, multidrug resistance- associated protein; NOD(c3c4), 
non- obese diabetic (with B6/B10 region on chromosomes 3 and 4); PBC, primary biliary cholangitis; PDH- E2, E2 subunit of the pyruvate dehydrogenase; PFIC, progressive familiar 
intrahepatic cholestasis; PSC, primary sclerosing cholangitis; TNBS, 2,4,6- trinitrobenzenesulfonice acid; Treg cells, regulatory T cells.
1Department of In Vitro Toxicology and 
Dermato- Cosmetology, Vrije Universiteit 
Brussel, Brussels, Belgium
2Gut- Liver Immunopharmacology Unit, 
Basic and Applied Medical Sciences, Liver 
Research Center Ghent, Faculty of Medicine 
and Health Sciences, Ghent University, 
Ghent, Belgium
3Hepatology Research Unit, Internal 
Medicine and Paediatrics, Liver Research 
Center Ghent, Faculty of Medicine and 
Health Sciences, Ghent University, Ghent, 
Belgium
Correspondence
Lindsey Devisscher, Corneel Heymanslaan 




This work was supported by grants of the 
Research Foundation Flanders, Belgium and 
the Scientific Fund Willy Gepts, Belgium and 
the Center for Alternatives to Animal Testing 
at Johns Hopkins University, USA.
Handling Editor: Emma Andersson
Abstract
Cholestatic liver disease denotes any situation associated with impaired bile flow 
concomitant with a noxious bile acid accumulation in the liver and/or systemic cir-
culation. Cholestatic liver disease can be subdivided into different types according 
to its clinical phenotype, such as biliary atresia, drug- induced cholestasis, gallstone 
liver disease, intrahepatic cholestasis of pregnancy, primary biliary cholangitis and 
primary sclerosing cholangitis. Considerable effort has been devoted to elucidating 
underlying mechanisms of cholestatic liver injuries and explore novel therapeutic 
and diagnostic strategies using animal models. Animal models employed according to 
their appropriate applicability domain herein play a crucial role. This review provides 
an overview of currently available in vivo animal models, fit- for- purpose in modelling 
different types of cholestatic liver diseases. Moreover, a practical guide and work-
flow is provided which can be used for translational research purposes, including all 
advantages and disadvantages of currently available in vivo animal models.
K E Y W O R D S
drug- induced cholestasis, in vivo modelling, intrahepatic cholestasis of pregnancy, primary 
biliary cholangitis, primary sclerosing cholangitis
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benign recurrent intrahepatic cholestasis (BRIC), intrahepatic drug- 
induced cholestasis (DIC), gallstone disease, iatrogenic cholestatic 
liver diseases, intrahepatic cholestasis of pregnancy (ICP), primary 
biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and 
progressive familiar intrahepatic cholestasis (PFIC).3- 7 The multifac-
eted liver disease biliary atresia can have devastating consequences 
including progression into end- stage cirrhosis.8 The diagnosis of bil-
iary atresia is based on excluding various causes of neonatal chol-
estasis, consequently by the time of diagnosis the extrahepatic bile 
ducts are often already completely obstructed.8,9 The incidence of 
neonatal cholestasis has been estimated to be 1 in 2500 new- born 
children, from which about 34%- 43% have biliary atresia.9- 11 PFIC 
and BRIC are two different forms of familial intrahepatic cholestasis 
with autosomal recessive inheritance.7 PFIC can be subdivided into 
three different types, from which type 1 is cause by a mutation in 
the ATPase phospholipid transporting 8B1 (ATP8B1) gene, type 2 by 
a mutation in the gene encoding the bile salt export pump (BSEP) 
and type 3 by a mutation in the gene encoding multidrug resistance 
protein 3 (MDR3).6 PFIC is considered a rare disease typically pre-
senting with cholestasis during infancy or childhood.12 BRIC was 
also found associated with mutations in ATP8B1 and BSEP, defined 
as BRIC type 1 and type 2 respectively. BRIC represents a less se-
vere cholestatic phenotype characterized by intermittent recurrent 
cholestatic episodes, with extensive pruritus.7 Iatrogenic cholestatic 
liver diseases constitute a group of liver diseases resulting from an 
invasive surgery, including biliary complications evoked by a living 
donor liver transplantation. Adult recipients from living donor liver 
transplantation were reported to develop biliary complications in 
15%- 40% of the cases, including biliary stricture (anastomotic or 
non- anastomotic), bile leakage, bile duct obstruction, sphincter of 
Key points
• There are still significant gaps in the mechanistic un-
derstanding of different types of cholestasis, including 
biliary atresia, drug- induced cholestasis, gallstone liver 
disease, intrahepatic cholestasis of pregnancy, primary 
biliary cirrhosis and primary sclerosing cholangitis.
• A better understanding of currently available animal 
models is urged with their specific properties, since 
inadequate models may inherently determine a biased 
research outcome.
• This review provides a practical guide for researchers in 
the field of translational hepatology by providing a sche-
matic overview of available animal models for choles-
tasis, including their individual and general advantages 
and disadvantages relevant for a specific applicability 
domain.
F I G U R E  1   Schematic overview of the pathogenesis of cholestatic liver injury. Cholestasis can be induced by a number of factors 
including, noxious compounds, infection, obstruction of bile flow, disturbance in the intestinal microbiota or genetic abnormalities.26,244 
These initiating factors evoke an inflammatory injury on hepatocytes and/or cholangiocytes, which may result in activation of hepatocytes, 
fibroblasts and cholangiocytes.48,244 These mature cells, may, in its turn, start to proliferate and cause fibrosis in the liver and/or bile duct.244 
In primary sclerosing cholangitis, fibrosis is typically accompanied by the ‘onion skinning’ around the bile ducts.186 Moreover, fibrosis might 
in some cases progress into cirrhosis or even carcinoma (hepatocellular carcinoma or cholangiocarcinoma).245 This figure was created with 
Biorender Software. IL- 1β, interleukin 1β; PSC, primary sclerosing cholangitis; TNF⍺, tumour necrosis factor ⍺
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Oddi dysfunction, etc Importantly, biliary complications remain the 
major cause of morbidity and mortality after living donor liver trans-
plantation.5,13 Additionally, biliary complications may also occur 
after invasive abdominal (ie gastrectomy and oesophagectomy), or-
thopaedic or cardiovascular surgeries and carry significant incidence 
of morbidity and mortality.14- 16 Gallstone liver disease is reported as 
major medical problem, especially in Western countries where it has 
a prevalence of about 15% in adults. Moreover, in Europe, gallstone 
liver disease is one of the common causes of hospitalization resulting 
from a gastrointestinal disease.17- 20 Approximately 20% of the pa-
tients will develop the typical symptoms, such as jaundice and biliary 
pain, or other types of complications in a time span of 15 years.19,21,22 
PBC and PSC have a prevalence ranging from 2 to 40 per 100,000 in-
habitants and 0 to 16 per 100,000 inhabitants.3,23 Ursodeoxycholic 
acid is the golden standard for safely and effectively treating PBC 
patients. Nevertheless, still about 15% of the PBC patients show a 
progressive disease that requires liver transplantation or in some 
cases results in death, despite ursodeoxycholic acid treatment.24,25 
For PSC, effective treatment is, thus far, still non- existing, presum-
ably due to considerable gaps in the mechanistic understanding of 
the disease, which hampers the identification of potential targets.26 
More atypical causes of cholestasis, albeit not less important, in-
clude DIC and ICP.3 ICP is of high clinical relevance considering their 
worldwide incidence ranging from 0.2% up to 25% and risk on pre-
term birth, respiratory distress syndrome and still birth.27- 30 DIC is in 
73% of the cases evoked by single- prescription medication, mainly 
cardiovascular, anti- inflammatory, antidiabetic and anti- infectious 
drugs.31 DIC can cause a tremendous financial loss for pharmaceuti-
cal companies, mostly due to early drug retraction from clinical tri-
als. This can partly be explained by the fact that current preclinical 
animal models as well as preclinical in vitro models only predict 50%- 
60% of all drug- induced liver injuries, including DIC.31- 34 A better 
understanding of currently available animal models with their spe-
cific properties is, therefore, highly demanded, since an inadequate 
model will inherently determine a biased research outcome.
This review provides a state- of- the- art overview of currently 
available surgery- induced, genetically modified, chemical- induced, 
viral- induced and combination rodent models for different types of 
cholestasis (ie biliary atresia, DIC, gallstone liver disease, ICP, PBC 
and PSC) together with their characteristics, individual assets, draw-
backs and applicability domain, which serves as a tool for research-
ers in the field of translational hepatology (Tables 1 and 2).
2  | PATHOPHYSIOLOGY OF CHOLESTATIC 
LIVER DISE A SES
2.1 | Gallstone liver disease
Gallstones are hardened deposits of digestive fluid bile, which 
develop within the gallbladder. They develop when there is an 
imbalance in the chemical constituents of bile, which results in pre-
cipitation of the components.20 Three main pathways have been 
identified in the formation of gallstones, cholesterol supersatura-
tion, excess of bilirubin and disturbance in the functionality of the 
gallbladder. In a healthy situation, bile is able to dissolve the amount 
of cholesterol excreted through the liver, but in case of excessive 
cholesterol biosynthesis or excretion cholesterol may precipitate as 
crystals and evolve to stones (ie cholesterol supersaturation).20,21,35 
The yellow pigment bilirubin is released upon degradation of red 
blood cells. In some haemolytic conditions (eg hereditary sphero-
cytosis and sickle cell disease), red blood cell disruption is abnor-
mally high resulting in an overload of bilirubin, which sometimes 
lead to gallstone formation, referred to as pigment stones.20,21,36,37 
Finally, gallbladder hypomotility or even impaired contractility can 
perturb the effective clearance of bile in the gallbladder. The latter 
may result in a highly concentrated bile, which may, in turn, lead to 
gallstone formation.21,38 Symptoms and complications of these gall-
stones can occur when the stones obstruct bile ducts and/or cystic 
ducts. A temporary obstruction of the cystic duct characterized as 
cholelithiasis is believed to be short- lived and results in biliary pain. 
A more persistent obstruction occurs when a large stone gets per-
manently lodged in the neck of the gall bladder (cystic duct) often 
leading to acute cholecystitis. Other types of complications can also 
develop depending on the location of gallstone obstruction. As such, 
obstruction of the common bile duct causes choledocholithiasis and 
jaundice while obstructing the ampulla in the distal portion of the 
bile duct may result in gallstone pancreatitis.21,39
2.2 | Biliary atresia
Biliary atresia is a severe inflammatory and fibrosing cholangiopa-
thy of infancy with an obstruction of the extrahepatic bile ducts, 
which can rapidly progress into end- stage cirrhosis. Intrahepatic 
bile ducts are not hindered yet, are observed to be hyperplastic 
and embedded in portal tracts with varying levels of inflammation 
and fibrosis, and lobules with features of cholestasis and increased 
multinucleated hepatocytes.8,40 Clinically, the disease is typified 
by pathological jaundice with direct or conjugated hyperbilirubi-
naemia, hepatosplenomegaly, acholic stool and the onset of symp-
toms in the first months of life.8,41 Precise clinical phenotyping 
might differ between the perinatal and embryonic form, and cyst- 
associated or cytomegalovirus- associated variants of the disease. 
Perinatal biliary atresia also referred to as non- syndromic biliary 
atresia represents the biggest subgroup with approximately 80% 
of the biliary atresia patients, characterized by a jaundice- free pe-
riod after birth.8,42 The embryonic form occurs in about 10% of the 
affected infants and show an earlier onset of jaundice (at birth) to-
gether with non- hepatic congenital malformation, such as splenic 
abnormalities.8,43,44 Cystic biliary atresia is defined by a cystic 
malformation near the obstructed common bile duct, occurring in 
about 8% of the patients. Cytomegalovirus- associated biliary atre-
sia shows a poor bile drainage and carries the highest risk of death. 
The incidence of this form is highly variable based on geography as 
well as the detection methodology used (eg lymphocyte activation 
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to cytomegalovirus proteins with or without other biochemical 
markers).8,45 Several factors have been described in the pathogen-
esis, including abnormal foetal or prenatal circulation, genetic fac-
tors, embryogenesis defects, an abnormal inflammatory response, 
autoimmunity, viral infection and environmental toxins.8
2.3 | Drug- induced cholestasis
Different types of DIC can be distinguished depending on (i) the lo-
cation of the insult, intrahepatic DIC versus extrahepatic DIC, (ii) the 
reversibility of the insult, acute DIC versus chronic DIC and (iii) the 
clinical phenotype of the insult, cholestasis without hepatitis, with 
hepatitis or with bile duct injury.46 Clinical symptoms may include 
jaundice or, when associated with parenchymal liver injury, non- 
specific symptoms, such as anorexia, nausea, fatigue and malaise.46 
Moreover, chronic DIC may also be accompanied by xanthomas, 
pruritus and melanoderma.46,47 Increasing efforts have been made 
to identify a set of mechanisms involved in all these different types 
of DIC. In this regard, inhibition of the BSEP was earlier denoted as 
a key molecular initiating event. Inhibiting the transporter involved 
in bile acid export may result in an accumulation of bile acids in the 
hepatocytes. In turn, bile acid accumulation was observed to trigger 
two types of cellular responses, namely a deteriorative response and 
an adaptive response. The deteriorative response is characterized by 
inflammation, oxidative stress, opening of the mitochondrial mem-
brane permeability pore and cell death. The adaptive response is the 
curious phenomenon of cholestasis, as this type of cellular response 
strives to counteract cholestasis by regulating nuclear receptors in-
volved in bile acid homeostasis.48,49
2.4 | Intrahepatic cholestasis of pregnancy
ICP is a cholestatic liver disease that refers to the sporadic occur-
rence of recurrent jaundice, pruritus, increased bile acid levels and/or 
elevated alanine/aspartate aminotransferase during the last trimes-
ter of pregnancy, sometimes resulting in foetal risks, such as preterm 
birth, respiratory distress syndrome or stillbirth.27- 29 There are still 
a lot of uncertainties in the aetiology of ICP. Genetic, environmental 
and hormonal factors are all believed to contribute to the pathogen-
esis of ICP. Accordingly, mutations in the MDR3 have been estimated 
to account for up to 15% of all ICP cases.29,50,51 Additionally, oestro-
gen is proven to play an important role in ICP. Oestrogen reaches 
its maximum concentration in the last trimester of pregnancy, in 
which ICP occurs most frequently. Twin and triplet pregnancies with 
increased oestrogen levels appear to be more susceptible for ICP 
compared to single gestations. Finally, women with a family or per-
sonal history of ICP were seen to develop ICP when treated with 
high doses of oestrogen oral contraceptive.52,53 Environmental fac-
tors that have been identified include an increased incidence of ICP 
associated with increased plasma levels of selenium, which varies 
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since the pathophysiology is still unresolved. Ursodeoxycholic acid 
is being supported as first- line therapy in ICP with beneficial effects 
on the mother, foetus and new- borns.55,56
2.5 | Primary biliary cholangitis
PBC is a slowly progressive cholestatic liver disease with an impor-
tant autoimmune aspect. This autoimmune disease is characterized 
by immune- mediated destruction of the intrahepatic bile ducts and 
portal inflammation. In a more advanced stage of the disease, loss 
of bile ducts may lead to diminished bile secretion, accumulating 
noxious substances within the liver, fibrosis, cirrhosis and ultimately 
liver failure. Accordingly, four different histological stages can be 
distinguished during PBC: (i) portal inflammation with or without 
‘florid’ bile duct lesions (ie intense inflammatory infiltration and 
necrosis around bile ducts), (ii) enhanced periportal lesions accom-
panied by interface hepatitis, (iii) abnormalities in the hepatic archi-
tecture and several fibrous septa and finally (iv) cirrhosis. Typical for 
PBC is the seropositivity for antimitochondrial antibodies (AMAs) 
towards the E2 subunits of 2- oxo- acid dehydrogenase complexes, 
such as pyruvate dehydrogenase (PDH- E2).57 AMAs are present in 
90%- 95% of the patients and can often be detected years before 
clinical symptoms, including fatigue, pruritus, jaundice, xanthomas, 
osteoporosis and dyslipidaemia.57- 59 The pathogenesis of PBC still 
remains to be further elucidates; however, an important genetic as-
pect has already been identified. The latter is related to an increased 
susceptibility in first- degree relatives 60 but a full characterization 
of the exact genetic influences is still missing.61,62 PBC primarily af-
fects woman, with a ratio 10 to 1 versus men, presumably related to a 
higher incidence of X- chromosome monosomy in lymphoid cells.57,63 
Environmental factors play an additional important role in PBC. 
Several causatives have been proposed to initiate a strong autoim-
mune response due to molecular mimicry and cross reactivity with 
human pyruvate dehydrogenase complex autoepitopes, including 
bacteria, viruses and environmental chemicals.57,64
2.6 | Primary sclerosing cholangitis
PSC is a long- term, chronic liver disease featured by inflammation 
and fibrosis of intra- and/or extrahepatic bile ducts, leading to end- 
stage liver disease and reduced life expectancy. PSC primarily af-
fects young, middle- aged men. Most patients complain of right 
upper quadrant abdominal pain, pruritis, fatigue and jaundice. In 
addition, hepatomegaly and splenomegaly are regularly observed 
in PSC patients. 10%- 20% of PSC patients spontaneously develop 
cholangiocarcinoma, making this a very dangerous liver disease.65 
Interestingly, PSC is also closely associated with inflammatory bowel 
diseases (IBD), with up to 70% of the PSC patients having underlying 
IBD, particularly ulcerative colitis. PSC- IBD represents a phenotypi-
cally different disease with a higher risk of hepatobiliary and colo-
rectal malignancy compared to non- IBD- PSC. Unfortunately, the 
link between PSC and IBD is incompletely understood.66- 69 Both he-
reditary and environmental factors were shown to contribute to PSC 
development. It has been hypothesized that genetically predisposed 
pathways may initiate a persistent injury on cholangiocytes lining the 
bile ducts after being exposed to an environmental source.26,65 With 
respect to the genetic susceptibility, a large cohort genome- wide as-
sociation study showed a strong correlation with specific human leu-
kocyte antigens (HLA) class I, II and III regions.26,70 Recently, novel 
insights were also gathered with regard to the role of peribiliary 
glands and the biliary tree stem cell compartment in the pathogen-
esis of PSC and related carcinogenesis.71- 73 There are three subtypes 
established for PSC being (i) classic PSC, affecting small and large 
bile ducts; (ii) small- duct PSC, affecting only small bile ducts and (iii) 
PSC associated with autoimmune hepatitis, affecting small and large 
bile ducts.65
3  | SURGERY- INDUCED RODENT MODEL S
3.1 | Obstructive cholestasis
The most frequently used surgery- induced animal model of choles-
tasis relies on bile duct ligation (BDL), where a ligature is placed or 
surgical ligation is performed on the common bile duct. This surgical 
procedure creates an extrahepatic obstruction of the biliary system, 
which results in cholestasis and inflammation.74,75 The BDL model 
induces acute extrahepatic obstructive biliary lesions, reflecting 
the clinical setting of gallstone liver disease and biliary atresia.76- 78 
However, while BDL is stricto sensu an extrahepatic obstruction, the 
model has also been extensively used as platform for investigating 
the subsequent pathophysiological processes in hepatic morphol-
ogy and function resulting from obstructive cholestasis. The BDL 
model has therefore also been widely used to study PSC.74,75,79- 81 
The model was initially developed for rats, since they lack the gall-
bladder 82,83 and later successfully adapted to mice.84,85 BDL in mice 
causes jaundice, release of transaminases, elevated bilirubin serum 
levels accompanied by development of bile duct proliferation with 
leukocyte infiltration, which eventually results in liver fibrosis.86 In 
contrast to rats and humans, mice develop a biliary type of hepato-
cytic necrosis (bile infarcts) instead of apoptosis.86,87 Additionally, 
unlike rats, the gallbladder of mice can drastically dilate after BDL 
and subsequently perforate resulting in bilioperitoneum, which 
may burgeon into death. Two strategies are followed to avoid these 
events, namely removal of the gall bladder via a cholecystectomy 
and placement of a surgical clip on the cystic duct.88
In the last decade, modifications were also described of total 
BDL, including partial BDL and selective BDL.85,87,89 Selective BDL 
is defined as ligating the left hepatic bile duct before it enters the 
common bile duct, while in partial BDL, a single ligation around the 
common bile duct is performed with leaving a defined lumen that al-
lows a limited degree of bile flow.87 The advantage of selective BDL 
is that the cholestatic injury is solely located in the left hepatic lobe, 
wherein bile infarcts develops as well as infiltrating neutrophils.85,87 
16  |     GIJBELS Et aL.
Partial BDL exhibits a less extensive tissue injury compared to selec-
tive BDL, believed to better mimic obstructive cholestasis in humans 
compared to total BDL. It should however be noted that cholestasis 
in this model seemed to spontaneously resolve after already 5 days, 
as a result partial BDL is particularly eligible for modelling acute 
cholestasis.85
3.2 | Cholangiopathies
Recently, the bile duct injection technique has been reported in 
which bile ducts are directly accessed without causing harm to 
the hepatobiliary tissue.90- 92 Studies have been reported injecting 
different types of solutions in the bile ducts varying from a harm-
less phosphate buffered saline solution to toxic dimethyl sulfoxide 
solutions, plasmid solutions and exogenous compounds including 
oxazolone.90- 92 The model has great potential to mimic several chol-
angiopathies, such as biliary atresia, PBC and PSC, depending on the 
causative agent that is being injected. The biggest advantage of this 
surgical model is the minimal injury to neighbouring tissue of the 
biliary tree. However, an important obstacle is the small anatomic 
proportion of mice (gall bladder has a diameter of 1- 2 mm), which 
complicate access to the biliary tree. Other drawbacks are the risk 
of peritonitis and possible leakage of bile or the injected solvent into 
the abdominal cavity. Noteworthy, a clear sex difference has been 
observed in this model. Female mice are described with a higher 
postoperative morbidity and mortality compared to male mice.91
4  | GENETIC ALLY MODIFIED MICE 
MODEL S
Researchers have entered a new era of modelling human diseases 
concomitant with the emergence of genetically manipulating the 
laboratory mouse (Mus musculus). The mouse is particularly relevant 
due to its high degree of conversation with humans regarding its 
anatomy, physiology and genetics.93 Genetically modified models 
are sometimes referred to as ‘spontaneous’ models or described to 
‘spontaneously develop’ the respective liver pathology. The word 
‘spontaneous’ indicates the absence of surgical or toxic/infectious 
insults to induce cholestasis.52,94,95
4.1 | Drug- induced cholestasis
Malfunctioning of the BSEP, via drug inhibition, internalization, mu-
tations or altered expression, drastically affects the bile acid home-
ostasis and inhibition of this transporter has been denoted as the 
key triggering factor of DIC.48,49 Consequently, Bsep (Abcb11)- /-  mice 
may serve as an essential tool elaborating the consecutive effects 
of Bsep perturbance while identifying possible alternative bile acid 
transport systems. A shortcoming of this model is the development 
of mild non- progressive cholestasis, presumably due to the more 
hydrophilic properties of endogenous bile acids in mice compared 
to humans.96 The latter can be tackled by administering additional 
cholic acids to Bsep- /-  mice.97 Finally, Bsep- /-  mice can additionally 
serve as a model for studying different genetic forms of cholestasis 
characterized by Bsep mutations, such as progressive familial chol-
estasis 2 and benign recurrent intrahepatic cholestasis 2. However, 
this goes beyond the scope of this review paper and thus will not 
further be discussed.82,96
4.2 | Primary biliary cholangitis
The first model created to mimic PBC consists of MRL/lpr mice bear-
ing the lymphoproliferative (lpr) gene.98,99 This gene results in the 
spontaneous development of severe autoimmune diseases, includ-
ing lymphadenopathy, hypergammaglobulinaemia, glomerulone-
phritis, arthritis and Sjögren's syndrome.98 The latter is frequently 
associated with PBC.100 In accordance, MRL/lpr mice present PBC- 
like histological features and infiltration of inflammatory cells, such 
as cluster differentiation 4 (CD4) + T cells and AMAs. The latter, 
however, only occurs in about 50% of the mice. In addition, MRL/lpr 
mice exhibit several other clinical features, incompatible with human 
PBC, including divergent bilirubin serum levels and hepatobiliary 
enzymes.98,99 Ergo, development of additional models to study PBC 
urged, among them are mouse strains based on deficiencies in regu-
latory T (Treg) cells, including scurfy mice.101 Scurfy mice contain a 
missense mutation in the transcription factor Forkhead box protein 
3 (Foxp3) gene, essential in development, maintenance and func-
tion of Treg cells, resulting in complete abolition of CD4+ Foxp3+ 
Treg cells.102- 104 This experimental model was constructed on the 
assumption that mice genetically deficient in regulatory mechanisms 
that provide immune homeostasis, including naturally occurring Treg 
cells, would gain increased susceptibility for developing autoimmune 
diseases, such as PBC.102 Indeed, scurfy mice manifest a similar 
serological, immunological and histopathological profile, albeit on 
the background of a multi- system autoimmunity.101,104,105 A similar 
disease phenotype was achieved in transgenic mice that express a 
dominant negative form of transforming growth factor- β receptor 
restricted to T cells (dnTGF- βRII mice), and in knockout mice with ho-
mozygous interleukin 2 receptor α (IL- 2Rα) deficiency, both contain-
ing a prominent dysfunction in Treg cell function.101 Dysfunctional 
TGF- β signalling results in reduced tolerance towards autoantigenic 
proteins present in the liver and leads to a PBC- like liver disease, 
including the characteristic AMAs directed to mitochondrial autoan-
tigens, such as PDH- E2.106- 108 The discovery of PBC- like disease 
in a child with homozygous IL- 2Rα deficiency 109 gave rise to the 
construction of the IL- 2Rα- /-  mice.110 Accordingly, both human PBC 
and IL- 2Rα- /-  mice exhibit portal lymphoid infiltrates and increased 
numbers of cytokines.111 dnTGF- βRII and IL- 2Rα- /-  mice are espe-
cially interesting to study acute mechanisms and address the role 
of Treg cells in PBC.111,112 However, both models exhibit a coincid-
ing IBD, absence of granulomas and lack of progression into chronic 
cholestasis.105,111,113,114
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An additional model was later developed to reduce the num-
ber of Treg cells, by introducing a mutation that disables the anion 
exchange protein 2 (AE2) gene.101 AE2 encodes the Cl- /HCO3
-  
anion exchanger 2, which regulates the intracellular pH and tran-
sepithelial acid- base transport, including secretin- stimulated 
biliary bicarbonate excretion and proton gastric secretion. Thus, 
disturbed AE2 activity may have an influence on the bile acid 
equilibrium, but also gastric acid equilibrium. Regulation of pH 
appears an important aspect in modulating lymphocyte function. 
Indeed, mature Ae2a,b
- /-  mice show immunological and hepatobi-
liary characteristics similar to PBC, but equally also PBC- unlike 
alterations, including impaired gastric acid secretion and only 
30%- 80% AMA.113 A different strategy was used based on al-
tered T- cell functionality, called non- obese diabetic (NOD)c3c4.
mice. NOD mice develop an immune- mediated destruction of 
pancreatic β cells, which underlies human type I diabetes and 
were created in the hope of identifying specific loci linked to 
the occurrence of type I diabetes.115 This led to the discovery 
of complete abolishment of diabetes development when con-
genic segments from chromosomes 3 and 4 (NOD.c3 and NOD.
c4) were used to replace the identified specific loci for insulin- 
dependent diabetes (idd) in NOD mice. Rather than diabetes, 
these NOD.c3c4 mice develop an autoimmune biliary disease 
similar to PBC with a comparable immunologic and serologic pro-
file (ie AMAs towards PDH- E2).95,116 Nevertheless, NODc3c4.
mice also exhibit some PBC- unspecific features, including biliary 
dilation and cystic lesions and absence of chronic destructive 
cholangitis.114,117
No murine model was able to fully recapitulate the female pre-
ponderance present in human PBC, until the a new ‘designer’ mouse 
consisting of an adenylate- uridylate- rich element (ARE) deletion 
in the interferon γ gene that results in chronic expression of inter-
feron γ.118 ARE- Del- /-  mice represent a phenotype very comparable 
to human PBC, particularly on histopathological, immunological and 
serological levels. Above all, this mouse model is the pioneer in ex-
hibiting a female predominance in the matter of developing PBC, 
making this characteristic its biggest asset. Moreover, this specific 
advantage may finally open the research field in terms of elucidating 
the crucial mechanisms behind increased susceptibility of women in 
developing PBC.114,119,120
4.3 | Primary sclerosing cholangitis
One of the first genetically modified models to study hepatobiliary 
diseases related to PSC was described in 1994, the Mdr2- /-  mice.121 
The Mdr2 gene, orthologue of the human MDR3 (ABCB4) gene, en-
codes a transporter that secretes phospholipids into bile across 
the canalicular membrane.122 As such, homozygous disruption of 
Mdr2 leads to absence of phospholipids (ie phosphatidylcholine) 
in bile and, thus interferes with the formation of biliary micelles 
resulting in liver injury.122 This injury particularly translates into 
cholelithiasis and sclerosing cholangitis. The model was initially 
used to investigate the role of PFIC3 but also showed several his-
tological lesions resembling human features of PSC, including the 
rapid progression into hepatic fibrosis.52,122- 124 The main draw-
back of the Mdr2- /-  mouse model for PSC is the absence of co-
existing IBD and the spontaneous development of hepatocellular 
carcinoma in in vivo models.94,123
A second model was created based on the observation that 
PSC and cystic fibrosis liver disease share several features being 
cholestasis, chronic inflammation and portal tract injury.125- 127 
Moreover, abnormalities in the liver cystic fibrosis transmembrane 
conductance regulator (CFTR) gene product were earlier denoted 
to play a key role in the development of cholestasis in cystic fibro-
sis patients and, vice versa, mutations in the CFTR gene were also 
reported in PSC patients.127,128 Hence, it was hypothesized that 
Cftr- /-  mice, harbouring an exon 10 deletion in the Cftr gene, might 
also develop a similar cholestatic liver injury. Cftr- /-  mice have 
been reported to, indeed, develop a progressive liver disease with 
focal cholangitis, inspissated bile and bile duct proliferation.129 
However, contrasting studies described Cftr- /-  mice to only exhibit 
an intestinal phenotype with mild or non- existing pathologies in 
other organs.81,130- 132 Moreover, this intestinal phenotype in Cftr- 
/-  mice resembles more a distal intestinal obstruction syndrome 
and meconium ileus rather than an IBD phenotype typical for 
PSC.69,129,133 Cftr- /-  mice, as such, are therefore rarely preferred as 
experimental model for PSC.
Erythropoietic protoporphyria is an inherited disorder typi-
fied by accumulating protoporphyrins as a result of reduced fer-
rochelatase activity. Severe malfunctioning in this ferrochelatase 
activity predisposes to the development of severe liver diseases 
with a progressive character, which frequently require liver trans-
plantation.134 Mice with a homogeneous mutation in genes en-
coding the ferrochelatase enzyme (fch/fch) display an increasing 
number of protoporphyrin deposits in the lumen of small and 
large bile ducts, resulting in an incomplete obstruction. The toxic 
effect of the accumulating protoporhyrin additionally causes 
damage and hepatocyte death.81,135 fch/fch mice present an ex-
treme cholestatic phenotype with increased serum liver enzymes, 
increased bile salt levels and conjugated hyperbilirubinaemia, yet 
bile formation remains unchanged.136 Not much is known about 
this model. A more in- depth study is needed to characterize the 
longitudinal changes of fch/fch mice as well as underlying patho-
genetic mechanisms.
5  | CHEMIC AL-  INDUCED RODENT 
MODEL S
Chemical- induced cholestasis is a well- recognized problem attrib-
uted to compounds, such as drugs, pesticides, food additives, cos-
metic ingredients or industrial compounds.137,138 Different types 
of cholestatic liver injuries have been identified depending on the 
causative agent, varying from (hepato- )canalicular, hepatocellular to 
ductular cholestasis.139
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5.1 | Drug- induced cholestasis
Chlorpromazine is an antipsychotic drug, which belongs to the 
largest class of first- generation phenothiazines.140 Although chlor-
promazine is one of the three listed medicines in the World Health 
Organization's Essential Drug List for treating psychotic disorders, 
the drug contains many adverse effects, among which cholestasis.141 
Chlorpromazine is believed to induce cholestasis via direct BSEP in-
hibition in accessory to repressing BSEP and MDR3 gene expres-
sion.142 Chlorpromazine has been commonly used to induce DIC in 
rodents while investigating its underlying mechanisms and the pro-
tective effect of chemicals against cholestasis.143,144
Cyclosporin A is used to prevent graft rejection after organ 
transplantation. The two most serious side effects observed during 
cyclosporin A treatment are nephrotoxicity and hepatotoxicity, from 
which the latter is delineated as cholestasis with low to moderate 
hyperbilirubinaemia.145 Cholestasis is presumably triggered by a 
number of factors, including direct inhibition and internalization of 
BSEP, disruption of the cytoskeleton and altered permeability of the 
canalicular membrane.145- 148 Similar to chlorpromazine, cyclosporin- 
A- treated rodents have been extensively employed as experimental 
model for DIC.145,148- 151
5.2 | Gallstone liver disease
In 1964, Tepperman et al discovered that feeding mice a 
cholesterol- cholic acid containing diet results in the formation 
of cholesterol gall stones in mice.152 This lithogenic diet contains 
high fat, high cholesterol and 0.5% cholic acid. The combination of 
cholic acid with cholesterol is essential, cholesterol alone cannot 
induce gallstones.152 Fujihera et al revealed the significant genetic 
contribution to gallstone formation in inbred mice.153 Resultantly, 
numerous studies were performed on different mouse strains 
striving to identify the candidate genes behind the increased sus-
ceptibility towards gallstone development, among which Lith1 and 
Lith2 genes are believed to be major players.154- 157 Additional re-
search are focussed on the impact of nuclear receptors, intesti-
nal microbiota, gender and comorbidities, such as non- alcoholic 
fatty liver disease, diabetes and obesity in the occurrence of 
gallstones.157
5.3 | Intrahepatic cholestasis of pregnancy
The first case of unexplained pruritus and jaundice in the last 
trimester of pregnancy was notified in 1883.158 Still, the disease 
remained unnoticed until mid- 1950s.159 Researchers started to 
highlight its importance and spread some of the drastic conse-
quences the disease withholds, including premature births, fetal 
distress or even stillbirths.160 As a result, research related to this 
subject was increased and resulted in the discovery of oestro-
gens, like estradiol- 17β- D- glucuronide, as inducers of reversible 
cholestasis in animals.27,161 Estradiol- 17β- D- glucuronide inhib-
its BSEP and MDR1 transporters, initiates an internalization of 
transporters BSEP and multidrug resistance- associated protein 2 
(MRP2) and increases the permeability of tight junctions.146,161,162 
Administration of the synthetic ethinylestradiol or estradiol- 17β- 
D- glucuronide to rodents can be used to study the underlying 
mechanisms of ICP as well as DIC, since oestrogens are often 
used in oral contraceptives and hormone substitution therapies (ie 
menopausal hormone therapy).163- 165
5.4 | Primary biliary cholangitis
2- octynoic acid and 2- nonynoic acid are chemicals regularly used as 
ingredients in food additives and perfumed cosmetics, such as toi-
let waters, soaps, detergents, lipstick, perfumes and facial creams, 
thanks to their violet scent.137,166 2- octynoic and 2- nonynoic acid 
are mimics of lipoic acid and replace the lipoyl group of the immuno-
dominant E2 domain of PDH (ie PDH- E2), thereby generating a high 
specific and reactive antimitochondrial response.166 This was also 
demonstrated in patients suffering from PBC, who presented an in-
creased reactivity towards PDH- E2 coupled with 2- octynoic acid.167 
Accordingly, a xenobiotic- induced model was designed by means of 
administering 2- octynoic acid coupled with bovine serum album to 
mice.168- 170 These mice manifest auto- immune cholangitis, concur-
rent with the typical AMAs of PBC.170
5.5 | Primary sclerosing cholangitis
α- naphtylisothiocyanate (ANIT) is a chemical used for preparation 
of cationic aromatic urethane.137 The compound is also well known 
among researchers for adequately inducing cholestasis in rats and 
mice,79,171 by specifically targeting bile duct epithelial cells followed 
by hepatocellular necrosis.137,172 Chronic and recurrent exposure to 
ANIT via the diet resembles an experimental setting of chronic chol-
angitis, bile duct hyperplasia and peribiliary fibrosis.172- 174 Moreover, 
mechanisms underlying peribiliary fibrosis in chronic ANIT models 
show similarities with other chronic cholestasis models, such as 
long- term BDL and Mdr2- /-  mice.172
3,5- diethoxycarbonyl- 1,4- dihydrocollidine (DDC) is a second 
compound found to induce cholestasis. DDC is a porphyrinogenic 
agent and strong initiator of δ- aminolevulinate synthetase.137,175 
Administration of DDC induces an increasing secretion of hepato-
toxic protoporphyrins, concomitant with formation of protoporhy-
rin plugs. The latter induces an obstruction in the small bile ducts, 
which initiates cholestasis.176 Moreover, DDC- induced cholestasis 
is typified by sclerosing cholangitis and pronounced biliary fibrosis 
accompanied by ductular proliferation.135,176,177 DDC feeding to ro-
dents can therefore be applied to investigate (xenobiotic- induced) 
chronic cholangiopathies.82,177 Furthermore, lithocholic acid, a nox-
ious endogenous bile acid, also induces cholestasis when present 
in abnormally high concentrations.178,179 Accordingly, the effect 
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of this endogenous bile acid has been widely studied in rodents 
to understand the potential role of the bile acid in the pathogen-
esis of cholestasis.180- 184 It has been postulated that cholestasis in 
lithocholic- acid- administered mice results from partial obstruction 
of the bile ducts, due to crystal formation (presumably lithocholic 
acid precipitates), along with bile infarcts, destructive cholangitis 
and periductal fibrosis within days.185 The lithocholic acid rodent 
model is claimed a valid short- term model in terms of investigating 
early changes in sclerosing cholangitis, thanks to the rapid induced 
changes after lithocholic acid administration.186
6  | VIR AL-  INDUCED MODEL S
6.1 | Biliary atresia
Although the aetiology of biliary atresia remains unclear, viral agents 
were proposed as one of the root causes of neonatal obstructive 
cholangiopathies, including biliary atresia.187 Moreover, several 
studies discovered the presence of pathologic viruses inside the liver 
of biliary atresia patients namely, rotavirus,188,189 reovirus,190,191 cy-
tomegalovirus 192,193 and human papillomavirus.194 Together with 
these findings, a first murine model was developed based on the in-
oculation of the rhesus rotavirus to new- born mice, which rendered a 
biliary atresia- like obstruction of extrahepatic bile ducts.195 Later on, 
this model has been frequently used to study disease mechanisms 
of biliary atresia.196- 198 Unfortunately, this model contains several 
practical limitations, including timing and dosing of the virus, which 
harms the reproducibility in addition to injection- related injury to 
abdominal organs, inter- strain differences and a low survival rate.199 
Bile duct proliferation and lymphocyte infiltration inside the portal 
triads are apparent in the model, resembling features of human bil-
iary atresia, albeit without liver fibrosis.199
7  | COMBINATION MODEL S
To achieve a better reflection of the in vivo situation, well- 
acknowledged rodent models can be combined and yield an improved 
rodent model of cholestasis. These combination models regularly 
consist of genetically modified rodent models or a surgery- induced 
model merged with a chemical- induced rodent model.97,127,200- 202
7.1 | Drug- induced cholestasis
BSEP disturbance is well known as one of the key players in DIC, 
yet Bsep- /-  mice only show mild non- progressive cholestasis and lack 
important histopathological features of cholestasis. Adding cholic 
acids to the diet of Bsep- /-  mice can be used to overcome this draw-
back by (i) altering the hydrophobicity of the bile acid pool, (ii) satu-
rating bile acid hydroxylation and (iii) resulting in a more pronounced 
intrahepatic accumulation of hydrophobic bile acids. Accordingly, 
male Bsep- /-  mice supplemented with cholic acids manifested severe 
progressive cholestasis associated with periportal fibrosis, inflam-
mation and cell death.97,203
7.2 | Primary sclerosing cholangitis
Next to liver injury, about 70%- 86% of the PSC patients present an 
IBD, most frequently ulcerative colitis.26 To investigate concomitant 
IBD presentation, additional toxics are used, including water- soluble 
dextran sodium sulphate (DSS).127,200,201 DSS is negatively charged, 
water- soluble and contains a highly variable molecular weight be-
tween 5 and 1400 kilodalton. This sulphated polysaccharide can be 
administered via drinking water, after which it can damage the mon-
olayer of epithelial cells lining the large intestine, hereby disrupting 
the upper barrier. As a result, intestinal contents, including bacte-
ria and their products, can disseminate into underlying tissue and 
cause an inflammatory response resulting in an IBD phenotype.204 
2,4,6- trinitrobenzenesulfonice acid (TNBS) is a chemical that can act 
as a hapten upon coupling with lysine moieties in proteins and pro-
voke a cell- mediated immune response.205 Initially, the compound 
was used for inducing inflammatory colitis in rats by means of intra-
colonic instillation of TNBS.206 The successful use of TNBS for evok-
ing an inflammatory disease of the colon raised the question what 
the inflammatory effect of TNBS would be on the liver, when locally 
administered. Consequently, new models were created that inject 
TNBS in the portal vein and in the ductus choledochus (ie intrachole-
dochal). TNBS administration in the portal vein yields an active liver 
injury in rats with PSC- characteristic antineutrophil cytoplasmic an-
tibodies, albeit without the involvement of the biliary tree 207 while 
intracholedochal injection does involve the biliary tree and induces 
a rather mild chronic cholangitis.205 Orth and colleagues made a first 
attempt in combining models by administering TNBS to BDL rats.202 
The latter resulted in a PSC- like appearance featured with irregu-
larities in the intra- and extrahepatic bile ducts, inflammation and 
the development of antineutrophil cytoplasmic antibodies. Although 
this model clearly shows an improvement compared to the single hit 
model, coinciding IBDs are still missing.202,208,209
To integrate the IBD component, previously defined in vivo mod-
els can also be conjugated with DSS feeding. To date, three such 
combinational models have been described in Cftr- /-  mice or Mdr2- 
/-  mice.127,176,200,201,204,210,211 Administering DSS to Mdr2- /-  mice re-
sults in an exacerbated sclerosing cholangitis along with increased 
ductular reaction and bridging fibrosis.201 Similarly, DSS can be ad-
ministered to Cftr- /-  mice, producing a significant increase in bile duct 
injury compared to the phenotype observed in Cftr- /-  mice. Yet, fi-
brosis remains absent and a clear association with CFTR dysfunction 
cannot be identified, since homozygote, heterozygote and wild- type 
mice manifest similar phenotypes.127 A follow- up study was per-
formed and indicates the need of three separate factors to elicit bile 
duct injury accompanied by progressive periductal fibrosis in Cftr- /-  
mice. Firstly, CFTR functionality should be harmed (ie Cftr- /-  mice). 
Secondly, mice should be exposed to profibrogenic activators (ie 
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DDC feeding). Thirdly, intestinal permeability needs to be disturbed 
(ie DSS feeding). Altogether, this one- of- a- kind model may serve as 
an ideal tool to elaborate the full pathogenic mechanism by which 
CFTR dysfunction predisposes fibrotic liver diseases.200
8  | DR AWBACKS OF CURRENT IN VIVO 
RODENT MODEL S
Liver diseases are a major cause of illness and mortality account-
ing for up to 2 million deaths per year.212,213 Many researchers have 
focused on unravelling the aetiology and pathogenesis of liver dis-
eases, including cholestatic liver disease. In vivo models have led to 
numerous breakthroughs in this field. However, they are also as-
sociated with inter- and intraspecies differences as well as model- 
specific bottlenecks, which urges an additional consideration to 
facilitate proper selection and application of the described models.
8.1 | Intraspecies differences
Three important aspects deserve specific attention, namely strain, 
gender and age. To exemplify, conflicting results were reported 
using Cftr- /-  mice and DDC- fed mice (partially) according to their 
genetic background. Cftr- /-  mice present a progressive hepatobil-
iary disease in C57BL/6 strains while other strains only exhibit a 
strong intestinal phenotype, but lack any abnormality in the liver.81 
In addition, DDC feeding appears to specifically result in the high-
est degree of large duct disease when using Swiss albino mice.177 
Similarly, inadequate gender selection can interfere considerably in 
establishing a sensitive model of cholestasis. Indeed, male mice were 
considered more suitable for BDL than female counterparts because 
of lower mortality rates; however, the latter does not relate to Sv129 
mice.86,214 Gender differences may also enhance the modelling of 
PBC or PSC, considering their female or male preponderance, as 
is the case for the ARE Del- /-  mice model and Mdr2- /-  mice model 
respectively.58,118,124 Likewise, the age of an animal should not be 
neglected, as the inflammatory response may alter in function of the 
rodents’ age.215
8.2 | Interspecies differences
The interspecies differences that should be encountered when mod-
elling cholestasis include (i) a more hydrophilic bile acid composition 
in rodents compared to humans, (ii) differences in the substrate 
specificity of bile acid transporters, (iii) alterations in metabolic 
detoxification and (iv) hepatocellular excretion of bile acids and 
drugs.216,217 Moreover, Cftr- /-  knockouts and DDC feeding are not 
feasible in rats; hence, variation in the clinical phenotype between 
mice and rats may also occur.129,177,218,219 Experimental in vivo mod-
els should preferably be benchmarked towards human samples. 
This strategy could also identify additional crucial interspecies dif-
ferences, not yet established, and hence complement some missing 
gaps in the mechanistic understanding of the cholestatic pathology. 
It would be highly relevant to use human- derived in vitro models 
and in silico modelling, based on structural and/or physical- chemical 
parameters, in addition to in vivo models. These models lack the 
F I G U R E  2   Practical workflow for selecting of the most applicable in vivo rodent model considering the applicability domain, advantages 
and disadvantages. This figure was created with Lucidchart software. The selection of experimental models was based on the information 
available in literature, as such the most appropriate well- described models were integrated. AE2, anion exchange protein 2; AMA, 
antimitochondrial antibody; ARE- Del, (deletion in) adenylate- uridylate- rich element; BSEP, bile salt export pump; CFTR, cystic fibrosis 
transmembrane conductance regulator; DDC, 3,5- diethoxycarbonyl- 1,4- dihydrocollidine; DSS, dextran sodium sulphate; dnTGF- βRII mice, 
dominant negative form of transforming growth factor- β receptor restricted to T cells; IL- 2Rα, interleukin 2 receptor α; NODc3c4, non- obese 
diabetic with B6/B10 region on chromosomes 3 and 4; PBC, primary biliary cholangitis; PDH- E2, E2 subunit of the pyruvate dehydrogenase; 
PSC, primary sclerosing cholangitis; TNBS, 2,4,6- trinitrobenzenesulfonice acid
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burden of a complex environment, allow high- throughput screening 
and may further improve the accuracy in predicting cholestasis while 
keeping interspecies differences in mind.49,220
8.3 | Specific bottleneck within a model
In addition to inter- and intraspecies differences, it is of the utmost 
importance to be adequately informed about specific aspects of a 
certain model relevant for the respective applicability domain(s) 
(Table 1). Additionally, a practical workflow is provided that guides 
researchers to make an informed decision in the most appropriate in 
vivo rodent model currently available while considering the specific 
bottlenecks (Figure 2).
9  | CONCLUSION
Considerable fundamental clues have been unveiled with the genera-
tion of experimental animal models related to the pathophysiological 
mechanisms of biliary and cholestatic diseases. Although extensive 
information has been gathered in the last couple of decades with re-
gard to the mechanistic understanding of cholestatic liver diseases, 
still considerable gaps are left behind due to inadequate animal models 
exemplified by the difficulty of inducing the female preponderance of 
PBC and the coincidence of PSC and IBD. Although breakthroughs 
are made in the design of new models, which try to tackle these set-
backs, still no experimental animal is able to perfectly mimic the real 
cholestasis phenotype seen in humans. For this reason, we should 
acknowledge the specific limitation of each model and design novel 
models by means of combining multiple in vivo rodent models, hereby 
circumventing limitations while increasing the assets. A number of 
these combination models have already been described in the last 
decade but are still limited. Further exploration of these combination 
models will undoubtedly pave the way for improved resemblance of 
human cholestasis in vivo and provide the possibility of more accurate 
mechanistic and therapeutic studies.
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